TYSONS CORNER, VA, April 11, 2016 — Leidos (NYSE: LDOS) will work with Immunovaccine to develop a vaccine that aims to prevent the spread of the mosquito-borne Zika virus, ExecutiveBiz reported Friday.
The companies will integrate Immunovaccine’s DepoVax platform and Leidos’ Virtual Pharmaceutical Development Program in support of efforts to accelerate vaccine development and production, Leidos said Thursday.
“Our virtual pharma approach ensures that we are not beholden to a particular technology or laboratory, ” said Jerry Hogge, deputy president of Leidos’ health group.
About Executive Mosaic: Founded in 2002, Executive Mosaic is a leadership organization and media company. It provides its members an opportunity to learn from peer business executives and government thought leaders while providing an interactive forum to develop key business and partnering relationships. Executive Mosaic offers highly coveted executive events, breaking business news on the Government Contracting industry, and delivers robust and reliable content through seven influential websites and four consequential E-newswires. Executive Mosaic is headquartered in Tysons Corner, VA. www.executivemosaic.com